- Home
- TEI vs DSGN Comparison
TEI vs DSGN Comparison
Compare TEI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | DSGN |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.6M | 528.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TEI | DSGN |
|---|---|---|
| Price | $6.63 | $9.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 142.4K | ★ 331.1K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $2.60 |
| 52 Week High | $5.39 | $10.31 |
Technical Indicators
Market Signals| Indicator | TEI | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 62.42 |
| Support Level | $6.55 | $9.00 |
| Resistance Level | $6.70 | $9.67 |
| Average True Range (ATR) | 0.08 | 0.67 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 83.72 | 60.84 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.